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Abstract
Purpose: To assess the utility of deep learning in the detection of geographic atrophy (GA) from color
fundus photographs; secondary aim to explore potential utility in detecting central GA (CGA).
Design: A deep learning model was developed to detect the presence of GA in color fundus pho-
tographs, and two additional models to detect CGA in different scenarios.
Participants: 59,812 color fundus photographs from longitudinal follow up of 4,582 participants in the
Age-Related Eye Disease Study (AREDS) dataset. Gold standard labels were from human expert reading
center graders using a standardized protocol.
Methods: A deep learning model was trained to use color fundus photographs to predict GA presence
from a population of eyes with no AMD to advanced AMD. A second model was trained to predict CGA
presence from the same population. A third model was trained to predict CGA presence from the subset of
eyes with GA. For training and testing, 5-fold cross-validation was employed. For comparison with human
clinician performance, model performance was compared with that of 88 retinal specialists.
Main Outcome Measures: Area under the curve (AUC), accuracy, sensitivity, specificity, precision.
Results: The deep learning models (GA detection, CGA detection from all eyes, and centrality detec-
tion from GA eyes) had AUC of 0.933-0.976, 0.939-0.976, and 0.827-0.888, respectively. The GA detection
model had accuracy, sensitivity, specificity, and precision of 0.965 (95% CI 0.959-0.971), 0.692 (0.560-
0.825), 0.978 (0.970-0.985), and 0.584 (0.491-0.676), respectively, compared to 0.975 (0.971-0.980), 0.588
(0.468-0.707), 0.982 (0.978-0.985), and 0.368 (0.230-0.505) for the retinal specialists. The CGA detec-
tion model had equivalent values of 0.966 (0.957-0.975), 0.763 (0.641-0.885), 0.971 (0.960-0.982), and
0.394 (0.341-0.448), compared to 0.990 (0.987-0.993), 0.448 (0.255-0.641), 0.993 (0.989-0.996), and 0.296
(0.115-0.477). The centrality detection model had equivalent values of 0.762 (0.725-0.799), 0.782 (0.618-
0.945), 0.729 (0.543-0.916), and 0.799 (0.710-0.888), compared to 0.735 (0.445-1), 0.878 (0.722-1), 0.703
(0.332-1), and 0.626 (0.273-0.979).
Conclusions: A deep learning model demonstrated high accuracy for the automated detection of GA.
The AUC was non-inferior to that of human retinal specialists. Deep learning approaches may also be
applied to the identification of CGA. The code and pretrained models are publicly available at https:
//github.com/ncbi-nlp/DeepSeeNet.
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Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in individuals
older than 60 years of age in Western countries, and accounts for approximately 9% of blindness world-
wide.1–3 Late AMD takes two forms, neovascular and atrophic, though these may coexist in the same eye.
Geographic atrophy (GA) is the defining lesion of the atrophic form of late AMD. GA in AMD has been
estimated to affect over 5 million people worldwide.2, 4 Unlike for neovascular AMD, no drug therapies are
available to prevent GA, slow its enlargement, or restore lost vision; this makes it an important research
priority.5, 6 Rapid and accurate identification of eyes with GA could lead to improved recruitment of eligi-
ble patients for future clinical trials and eventually to early identification of appropriate patients for proven
treatments.
Since the original description of GA by Gass,7 clinical definitions have varied between research groups.8
In the Age-Related Eye Disease Study (AREDS), it was defined as a sharply demarcated, usually circular
zone of partial or complete depigmentation of the retinal pigment epithelium (RPE), typically with exposure
of underlying large choroidal blood vessels, at least as large as grading circle I-1 (1/8 disc diameter in
diameter).9 Sensitivity of the retina to light stimuli is markedly decreased (i.e., dense scotomata) in areas
affected by GA. The natural history of the disease involves progressive enlargement of GA lesions over time,
with visual acuity decreasing markedly as the central macula becomes involved.5
The identification of GA by ophthalmologists conducting dilated fundus examinations is sometimes
challenging. This may be particularly true for cases with early GA, comprising smaller lesions with less
extensive RPE atrophy. In addition, the increasing prevalence of GA (through aging populations in many
countries) will translate to greater demand for retinal services. As such, deep learning approaches involving
retinal images, obtained perhaps using telemedicine-based devices, might support GA detection and diagno-
sis. However, these approaches would require the establishment of evidence-based and ‘explainable’ systems
that have undergone extensive validation and demonstrated performance metrics that are at least non-inferior
to those of clinical ophthalmologists in routine practice.
Recent studies have demonstrated the utility of deep learning in the field of ophthalmology.10–18 Deep
learning is a branch of machine learning that allows computers to learn by example. As applied to image
analysis, deep learning enables computers to perform classification directly (unsupervised) from images,
rather than through the recognition of features prespecified by human experts. This is achieved by training
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algorithmic models on images with accompanying labels (e.g. color fundus photographs categorized manu-
ally for the presence or absence of GA), such that these models can then be used to classify new images with
similar labels. The models are neural networks that are constructed of an input layer (which receives, for ex-
ample, the color fundus photograph), followed by multiple layers of non-linear transformations, to produce
an output (e.g. GA present or absent). One recent deep learning model, DeepSeeNet,17 performed patient-
based AMD severity classification with a level of accuracy higher than a group of human retinal specialists.
Indeed, it also did this in an ‘explainable’ way, by simulating the human grading process, which may improve
levels of acceptability to ophthalmologists and patients. However, to the best of our knowledge, few studies
have focused specifically on GA,19–22 and the majority of these have concentrated on image segmentation
tasks rather than automated detection of GA.
The primary aim of this study was to assess the utility of deep learning for the detection of GA from
color fundus images. We also conducted experiments to assess the potential utility of deep learning for the
detection of central GA (CGA) from color fundus images.
Methods
Dataset
The dataset used for this study (training and testing) was from the AREDS. The AREDS was a multi-center,
prospective cohort study of the clinical course of AMD (and age-related cataract), as well as a phase III
randomized clinical trial of nutritional supplementation for treatment of AMD and cataract.23 Its primary
outcome was the development of advanced AMD, defined as CGA or neovascular AMD. The study design
has been described previously.23 In short, 4,757 participants aged 55 to 80 years were recruited between 1992
and 1998 at 11 retinal specialty clinics in the USA. Based on color fundus photographs, best-corrected visual
acuity, and ophthalmologic evaluations, participants were enrolled into one of several AMD categories.
Institutional review board approval was obtained at each clinical site and written informed consent for the
research was obtained from all study participants. The research was conducted under the Declaration of
Helsinki.
As described previously, at baseline and annual study visits, comprehensive eye examinations were per-
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formed by certified study personnel using standardized protocols. At the baseline, 2-year, and annual study
visits thereafter, stereoscopic color fundus photographs were taken of both eyes (field 2, i.e., 30° imaging
field centered at the fovea). Because of the inherent redundancy in a pair of stereoscopic photographs, for
each eye, only one of the pair of photographs was used in the current study. In general, the left image of the
pair was used, unless it was missing from the database, in which case the right image was used instead (∼
0.5%). As a result, a total of 59,812 color fundus images from 4,582 participants were extracted from the
AREDS dataset (Table 1).
Table 1: Characteristics of images and participants in each partition according to the presence of geographic
atrophy and central geographic atrophy.
Total Partition
1 2 3 4 5
Images 59,812 11,933 11,814 11,882 12,056 12,127
Participants 4,582 924 907 915 919 917
Age: Mean, years (SD) 69.4 (5.1) 69.5 (5.1) 69.4 (5.2) 69.4 (5.2) 69.6 (5.0) 69.2 (5.0)
Gender (% male) 44.3% 44.9% 44.4% 45.2% 44.7% 42.2%
Geographic atrophy 4.3% (n=2,585) 4.9% (n=588) 4.8% (n=571) 3.5% (n=420) 4.9% (n=586) 3.5% (n=420)
Central geographic atrophy 2.4% (n=1,455) 2.9% (n=344) 2.9% (n=347) 1.8% (n=216) 2.7% (n=325) 1.8% (n=223)
The ground truth labels used for both training and testing were the grades previously assigned to each
color fundus photograph by expert human graders at the University of Wisconsin Fundus Photograph Read-
ing Center. (These grading experts did not overlap at all with the 88 retinal specialists described elsewhere).
The Reading Center workflow is described in detail in AREDS Report number 69. In brief, a senior grader
(grader 1) performed initial grading of the photograph for AMD severity using a 4-step scale (where step 3
includes non-central GA and step 4 includes CGA), and a junior grader (grader 2) performed detailed grad-
ing for multiple AMD-specific features (including CGA and non-central GA). In the case of discrepancy
between the two graders, a senior investigator at the Reading Center would adjudicate the final grade. All
photographs were graded independently, that is, graders were masked to the photographs and grades from
previous visits. In addition, a rigorous process of grading quality control was performed at the Reading Cen-
ter, including the assessment for the inter-grader and intra-grader agreement overall and according to specific
AMD features.24 Inter-grader agreement was substantial for CGA (kappa 0.73). Analyses for potential “tem-
poral drift” were conducted by having all graders re-grade in a masked fashion the same group of images
annually for the duration of the study. The presence of GA was defined as a sharply demarcated, usually
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circular, zone of partial or complete depigmentation of the RPE, typically with exposure of underlying large
choroidal blood vessels, at least as large as grading circle I-1 (1/8 disc diameter in diameter).9 If present,
GA was categorized as central or non-central according to involvement of the ‘center point’ (Figure 1). In
this study, images where GA was present alongside signs of neovascular AMD (i.e., image graded positive
for both GA and neovascular AMD) were excluded from the dataset.
207,361 potentially eligible images
AREDS
Excluded: field 1 and 3 images, duplicated stereoscopic 
photographs, incompletely graded images by the reading 
center, and images with neovascular AMD
57,227 images 1,297 images
Within 
GA grid?
158 images1,130 images
no
no yes
yesquestionableno
yes
cGA
GA
Center 
point?
Center 
subfield 
< ½ DA?
Figure 1: Distribution of color fundus photographs from the Age-Related Eye Disease Study categorized
according to the presence and absence of geographic atrophy (GA) and central geographic atrophy (CGA).
Models
The deep learning models for predicting GA and CGA were built using the methods described in
DeepSeeNet.17 Specifically, three separate deep learning models were built: (i) one (‘GA model’) for iden-
tifying GA from a population of eyes with no AMD to advanced AMD, irrespective of central involvement,
(ii) one (‘CGA model’) for identifying CGA from a population of eyes with no AMD to advanced AMD, and
(iii) one (‘centrality detector model’) for identifying CGA from a population of eyes with GA (i.e., a model
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that assesses for central involvement, when GA presence is already known). All three models were binary
classification models. As shown in Table 1, there were 2,585 positive instances for the former (GA model)
and 1,455 for the latter two (CGA model and centrality detector model). The convolutional neural network
architecture used for all models was Inception-v3,25 which is a state-of-the-art convolutional neural network
for image classification. It contains 317 layers, comprising a total of over 21 million weights (learnable
parameters) that are subject to training.
The three models were pre-trained using ImageNet, an image database of over 14 million natural images
with corresponding labels, using methods described previously.17 (This very large dataset is often used in
deep learning to pre-train models. In a process known as transfer learning, pre-training on ImageNet is used
to initialize the layers/weights, leading to the recognition of primitive features (e.g., edge detection), prior
to subsequent training on the dataset of interest). During subsequent training, for all three models, the input
to the model was a color fundus photograph cropped to a square and scaled to 512 pixels. Cropping was
done by decreasing the longer dimension of the image to match the shorter dimension (keeping the center
point unchanged). We also applied a Gaussian filter to normalize the color balance.26, 27 We trained the deep
learning models using two commonly used libraries: Keras28 and TensorFlow.29 During the training process,
we updated the model parameters using the Adam optimizer (learning rate of 0.0001) for every minibatch
of 32 images. Model convergence was measured when the loss on the development set started to increase.
The training was stopped after 5 epochs (passes of the entire training set) once the accuracy values no longer
increased or started to decrease. All experiments were conducted on a server with 32 Intel Xeon CPUs,
using a NVIDIA GeForce GTX 1080 Ti 11Gb GPU for training and testing, with 512Gb available in RAM
memory.
Evaluation
For training and testing, we used the standard machine learning approach of five-fold cross-validation. This
consists of subdividing the total data into five equally-sized folds. We used three folds for training, one fold
for development (to optimize the hyperparameters and measure the convergence), and the remaining one fold
for testing. This process was repeated five times, reserving a different fold each time as the testing set. These
settings avoid overfitting the test set, as well as having the test set large enough to be representative. The
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cross-validation splitting (into the five folds) was performed randomly, at the participant level (i.e., without
stratification by disease status). All images from a single participant were present in only one fold. In addi-
tion, image augmentation procedures were used, as follows, in order to increase the dataset artificially (i.e.,
using additional synthetically modified data): (i) rotation, (ii) width shift up to 0.1, (iii) height shift up to 0.1,
(iv) horizontal flip, and (v) vertical flip. Each model was evaluated against the gold standard Reading Center
grades. We obtained the following metrics: overall accuracy, sensitivity, specificity, and precision (with 95%
confidence intervals). Outcomes were also evaluated using receiver operating characteristic (ROC) curves
and their corresponding area under the curve (AUC).
The performance of the models was compared with the performance of 88 human retinal specialists (in
terms of their pooled gradings). The retinal specialists had graded all color fundus photographs (as part of a
qualification survey used to determine AMD severity) at AREDS baseline; the grading was non-overlapping
(i.e., each image was graded by one retinal specialist only) and was independent of the Reading Center
grading, which was used as the ground truth.
Results
The ROC curves for the deep learning models are shown in Figure 2. For each model, five ROC curves are
displayed on the same graph, with each curve representing one of the folds tested (in the five-fold cross-
validation procedure). For comparison, the performance of the human retinal specialists (in terms of their
pooled gradings) on the same fold is shown as a single point, such that one point accompanies each of the five
curves. For the GA model, the five AUC values were 0.933, 0.952, 0.962, 0.964, and 0.976. For the CGA
model, the five AUC values were 0.939, 0.941, 0.955, 0.968, and 0.976. For the centrality detector model, the
five AUC values were 0.827, 0.833, 0.864, 0.884, and 0.888. Based on the ROC analysis, the performance
levels of the GA model were slightly superior to those of the retinal specialists; those of the CGA model
were slightly superior or similar, and those of the centrality detector model were generally inferior.
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(a) (b) (c)
Figure 2: Receiver operating characteristic curves for (a) the geographic atrophy model, (b) the central
geographic atrophy model, and (c) the centrality detector model.
The accuracy, sensitivity, specificity, and precision of the three models are shown in Table 2. The GA
model demonstrated high accuracy (0.965, 95% CI 0.959-0.971), attaining sensitivity of 0.692 (0.560-0.825)
and specificity of 0.978 (0.970-0.985). The sensitivity was substantially higher and the specificity slightly
lower than those of the human retinal specialists. The CGA model also demonstrated high accuracy (0.966,
0.957-0.975), with sensitivity of 0.763 (0.641-0.885) and specificity of 0.971 (0.960-0.982). Again, the
sensitivity was substantially higher and the specificity slightly lower than those of the retinal specialists.
The centrality detector model had accuracy of 0.762 (0.725-0.799), sensitivity of 0.782 (0.618-0.945), and
specificity of 0.729 (0.543-0.916). The accuracy and specificity were slightly higher than those of the retinal
specialists, while the sensitivity was substantially lower. For all three models, the precision was higher than
that of the retinal specialists.
Table 2: Performance of the three deep learning models: (i) geographic atrophy model (‘GA model’), (ii)
central geographic atrophy model (‘cGA model’), and (iii) centrality detector model.
GA detection cGA detection from all eyes cGA detection from eyes with GA
GA model Retinal specialists cGA model Retinal specialists Centrality detector Retinal specialists
model
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Accuracy 0.965 (0.959, 0.971) 0.975 (0.971, 0.980) 0.966 (0.957, 0.975) 0.990 (0.987, 0.993) 0.762 (0.725, 0.799) 0.735 (0.445, 1.000)
Kappa 0.611 (0.533, 0.689) 0.438 (0.304, 0.571) 0.501 (0.451, 0.552) 0.344 (0.156, 0.532) 0.513 (0.442, 0.584) 0.533 (0.176, 0.891)
Sensitivity 0.692 (0.560, 0.825) 0.588 (0.468, 0.707) 0.763 (0.641, 0.885) 0.448 (0.255, 0.641) 0.782 (0.618, 0.945) 0.878 (0.722, 1.000)
Specificity 0.978 (0.970, 0.985) 0.982 (0.978, 0.985) 0.971 (0.960, 0.982) 0.993 (0.989, 0.996) 0.729 (0.543, 0.916) 0.703 (0.332, 1.000)
Precision 0.584 (0.491, 0.676) 0.368 (0.230, 0.505) 0.394 (0.341, 0.448) 0.296 (0.115, 0.477) 0.799 (0.710, 0.888) 0.626 (0.273, 0.979)
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Discussion
The deep learning model showed relatively robust performance for the detection of GA from a population
of eyes with a wide spectrum of disease, from no AMD to advanced AMD. The ROC analysis demonstrated
that its performance was non-inferior to that of human retinal specialists. The results of this study highlight
the potential utility of deep learning models in identifying GA, based on simple color fundus photographs
without additional imaging modalities or other information. In addition, potential utility was demonstrated
for deep learning-based detection of CGA in two different scenarios, i.e., from a population of eyes with a
wide spectrum of disease and from a population of eyes already known to have GA. Each of these scenarios
might be relevant in different clinical or research settings.
To probe further the performance of the GA model that identifies GA presence/absence, particularly in
light of lower sensitivity than specificity, we performed an error analysis of false negative cases according to
GA area. The hypothesis was that the model performance may have been superior for large GA lesions and
inferior for small GA lesions, such that missed cases with small GA lesions might help explain suboptimal
model sensitivity. As part of the original Reading Center grading, GA area (within the AREDS grid) was
quantified into one of seven categories using the AREDS grading circles.9 We analyzed the proportions of
false negatives (GA cases missed by the model) according to the seven area categories. Table 3 demonstrates
that questionable and small GA lesions had a much higher false negative rate (62.9% for questionable and
78.9% for area < circle I-2), whereas large GA lesions had a much lower false negative rate (19.8% for
area ≥ 2 DA), with evidence of a dose-response effect. Hence, the model’s performance had (perhaps
understandably) lower sensitivity for small and questionable GA lesions. One contributing factor to this is
likely to be the relatively low number of instances during training, since the smaller GA categories accounted
for low proportions of the training set.
To probe further the performance of the CGA model that identifies CGA presence/absence, again in light
of lower sensitivity than specificity, we performed an error analysis of false negative cases according to the
two categories shown in Figure 1 (i.e., ‘center point with definite GA’ versus ‘center point with questionable
GA but central subfield with definite GA’). As before, we analyzed the proportions of false negatives (CGA
cases missed by the model) according to the two categories (Table 4). As expected, the latter category had
a higher false negative rate (31.6%) than the former category (21.5%). Hence, the model’s performance
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Table 3: False negatives of geographic atrophy detection categorized by the geographic atrophy area within
grid.
Area category Whole test set False negatives
Questionable 275 173 62.9%
Definite, area < circle I-2 38 30 78.9%
Area ≥ I-2 but < O-2 125 76 60.8%
Area ≥ O-2 but < ½ DA 192 90 46.9%
Area ≥ ½ DA but <1 DA 297 79 26.6%
Area ≥ 1 DA but <2 DA 403 95 23.6%
Area ≥ 2 DA 1,255 248 19.8%
had (perhaps understandably) lower sensitivity for cases with questionable involvement of the center point.
In future studies, possible approaches to improve the false negative rate in images with small GA lesions
might include the use of additional datasets, image augmentation, and generation of synthetic images. In
particular, further training on the AREDS2 dataset is likely to improve this aspect of performance, since the
dataset includes 1616 eyes with GA (of which 1,118 had GA area <0.75 disc areas at first appearance).5 In
the near future, deep learning might also be able to generate synthetic retinal images with GA (where small
lesions could be specified), for improved model training.30
Table 4: False negatives of central geographic atrophy detection categorized by involvement of the center
point and center subfield.
Area category Whole test set False negatives
Definite, center point < I-2 1,297 279 21.5%
Questionable center point, but center subfield area < ½ disc area 158 50 1.6%
In addition, for the false negative cases, we analyzed the fundus photographs and their accompany-
ing saliency maps (explained in the Supplementary information) for a random sample of 20 images. We
graded the photographs qualitatively using pre-specified criteria: (i) image quality, (ii) GA size, (iii) degree
of depigmentation in GA lesion(s), and (iv) other factors. Image quality was extremely poor in 5/20 and
moderately poor in 10/20. GA size was very small in 4/20 and extremely large (occupying almost all of the
photograph) in 2/20. Degree of depigmentation was very mild in 3/20. The most common other factor (in
11/20) was GA lesion features suggestive of prior neovascular AMD (even though the Reading Center grad-
ing for these images was negative for neovascular AMD); indeed, examination of previous Reading Center
11
gradings for the same eyes confirmed that, in 10 of these eyes, neovascular AMD had been graded posi-
tive at one or more previous study visits. Hence, one or more potential reasons for a false negative grading
(very poor image quality, very small GA size, very mild depigmentation, or features of previous neovascular
AMD) was found in 19/20 cases. The remaining case had a combination of moderately poor image quality
and moderately small GA lesion size. In addition, in 5/20 cases, the saliency maps demonstrated increased
signal concentrated in the GA lesion(s), despite the negative prediction.
We consider that these models, and future models arising from them, may be useful in several different
scenarios, including assistance in (i) clinical care, (ii) recruitment for clinical trials, (iii) population-based
screening for clinical care, and (iv) population-based screening for epidemiological research. Notably, GA
has been estimated to affect over 5 million people worldwide,2, 4 but it is likely that many of these individuals
remain undiagnosed, especially in countries with lower levels of access to retinal specialists. As regards clin-
ical care, the ongoing incorporation of deep learning into radiology and pathology is through augmentation
(rather than replacement) of human diagnosis. In ophthalmic care, it might be helpful for an optometrist,
general ophthalmologist, or even retinal specialist to have software like this available alongside traditional
clinical tools. The software would assist human diagnosis and decision-making, rather than replacing it. For
example, it could be used (with settings selected for high sensitivity) by an optometrist, alongside normal
examination procedures. Deep learning-assisted GA detection could lead to referral for consultation with a
retinal specialist. This approach might also lend itself well to telemedicine approaches, particularly in remote
areas. Ultimately, an integrated suite of tools like this might be helpful for augmented human evaluation of a
wide range of ophthalmic pathologies, such as AMD, diabetic retinopathy, and glaucoma. However, it would
be very important to perform prospective studies to compare the performance of clinicians with and without
assistance from deep learning systems.
As to assistance in recruitment for clinical trials, the number of clinical trials of drugs to slow GA
enlargement is likely to increase over the next decade. Models like these would enable rapid screening of
large numbers of individuals, to identify potential qualifying participants. If treatments that successfully
slow GA enlargement are identified and approved, the identification of patients with GA who may stand
to benefit from treatment may be aided by these models. Finally, as regards assistance in population-based
screening for epidemiological research, accurate data on GA prevalence and characteristics are important
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for understanding AMD pathophysiology and planning service provision. However, few modern population-
based studies have these data readily available. If models like this were used for rapid population-based
screening, large quantities of epidemiological data could be produced. For example, the UK Biobank study
contains color fundus photographs on 68,544 adult participants (with detailed accompanying data on medical
history, lifestyle, physical measures, and blood samples). Applying this model to the dataset would generate
a large volume of data on GA prevalence, with powerful links to the medical characteristics of the affected
participants. Similar approaches might be possible in the future, e.g. using the Million Veterans Program
and others.
There are several limitations to this study. First, the proportions of positive test cases (i.e., images
with GA and CGA) were relatively low. This limitation may be reflected in the higher rates of specificity
than sensitivity for the first two models. Second, model training and testing were carried out (necessarily)
in the context of a high prevalence of AMD, which is a controlled clinical trial rather than a real-world
scenario. The ideal setting for evaluating model performance in real-world scenarios (i.e., within a realistic
background of retinal diseases and findings) would be a population-based dataset, in which the presence of
GA and of other retinal findings had been rigorously graded by human reading center graders. However,
the AREDS participants did encounter ocular and systemic disease typical for an elderly population and
were not excluded from follow-up for these reasons. Therefore, many AREDS images contain signs of
diabetic retinopathy and other pathology (though this was towards the milder end of the disease spectrum,
particularly in earlier study years). Hence, model training and testing were performed in the presence of
co-existing retinal pathology, perhaps not unlike that expected in population-based studies. Despite this,
the GA detection model’s specificity was very high, suggesting that the algorithm did not confuse non-AMD
lesions with GA. As regards sensitivity, of the sample of 20 false negative cases, we observed no cases where
coexisting retinal pathology led to GA being missed.
However, we recommend that the present use case for these models (as currently configured) be limited
to research settings, such as in highlighting cases with the potential for enrollment into clinical trials. Before
clinical deployment, as with any novel diagnostic aid or test, external validation is required, and should be
conducted in the intended use setting(s). The performance of the models for populations like the AREDS,
with a very high prevalence of AMD and a lower (but non-zero) prevalence of other retinal diseases and
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lesions, is expected to be similar to that reported here. We anticipate that the performance may be similar
in adult population-based studies, since these also have a relatively low prevalence of non-AMD retinal
conditions, though performance might depend on the racial characteristics of the study population. For these
reasons, first, we have made freely available the models and code, so that other research groups may perform
testing in their own diverse datasets. Second, we are planning external validation studies using well-curated
population-based studies from different continents. Following demonstrations of robust external validity
and generalizability, these models (or newer models based on them) may be ready for deployment to assist
healthcare practitioners in specific clinical settings.
Third, this study is based on one imaging modality only. We used color fundus photographs for GA de-
tection because this imaging modality is the historical standard; color fundus photographs were used in, for
example, the AREDS and AREDS2 to define and classify AMD, i.e., to derive classification and prognostic
systems including the AREDS 9-step and simplified severity scales.31, 32 As such, color fundus photographs
are the most highly validated tools for AMD classification and the prediction of disease progression.33 They
have the additional advantages of (i) being the closest correlates to biomicroscopy, (ii) consisting of simple
datasets (unlike complex 3-dimensional datasets from optical coherence tomography (OCT)), and (iii) (un-
like fundus autofluorescence) being widely available and permitting assessment of GA central involvement
(without interference from macular pigment in the foveal region).
While OCT may be used increasingly to define GA in the future,34 few large standardized datasets
currently exist that have followed eyes sequentially for long periods using OCT with detailed accompanying
reading center grades and clinical information. Deep learning approaches to OCT datasets hold promise35 but
sophisticated software is required to process complex 3-dimensional datasets, and automated segmentation
of OCT data can be error-prone in disease. Ultimately, we anticipate that deep learning approaches to AMD
may be developed using multiple imaging modalities, first using each independently, then combined in a
multimodal fashion. In the meantime, the development and validation of deep learning models applied to
individual imaging modalities is an important first step.
In conclusion, deep learning demonstrated relatively robust performance for the automated detection of
GA. The performance was non-inferior to that of human retinal specialists. In addition, potential utility was
observed in the automated identification of CGA. The results of this study may serve as a benchmark for
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deep learning-based identification of GA from color fundus photographs. We are making the code and pre-
trained models publicly available at https://github.com/ncbi-nlp/DeepSeeNet. In this way,
the work may help stimulate the future development of automated retinal image analysis tools, not only in
the detection of GA, but also in the analysis of GA features including central involvement, multifocality, and
area quantification.
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Supplement
Saliency maps
To visualize important areas in the color fundus images (i.e., those areas that contributed most towards
classification), we applied image-specific class saliency maps to assess manually whether the deep learning
models were concentrating on image areas that human experts would consider the most appropriate to predict
geographic atrophy (GA) or central GA.36 The saliency map is widely used to represent the visually dominant
location in a given image; it helps highlight areas used by the deep learning algorithm for prediction and can
also provide insight into misclassified images. For example, the areas highlighted in the accompanying figure
are indeed areas with GA and central GA that are visually apparent in the color fundus images.
Original GA model
(a) (b)
Original cGA model
Figure 3: Representative color fundus photos (first column) side-by-side with overlaid saliency maps (second
column), generated by applying keras-vis37 to (a) the geographic atrophy (GA) model and (b) the central
geographic atrophy (CGA) model.
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